• Leveljump Healthcare (JUMP) has agreed to acquire an additional minority interest in Real Time Medical (RTM), Shaw Lens, and Shaw Vision
  • The company also updated shareholders on the progress of acquisitions announced September 28 and October 1
  • Leveljump announced that it has issued options to its three new independent directors, its two executive directors, and its CEO and CFO
  • Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology
  • Shares in Leveljump Healthcare Corp. (JUMP) are up 4.35 per cent, trading at $0.12 per share

Leveljump Healthcare (JUMP) has agreed to acquire an additional minority interest in Real Time Medical (RTM), Shaw Lens, and Shaw Vision.

Subject to regulatory approval, Leveljump will acquire an additional 2.3 per cent minority equity interest in Ontario-based RTM in exchange for 392,875 units at C$0.50 each.

Once the transaction is complete, Leveljump will own a 16.9 per cent interest in RTM.

The company has also exercised its right of first refusal to purchase a further minority interest in both Shaw Lens and Shaw Vision. If no other shareholders exercise their rights to the interest, Leveljump will acquire an additional 1.5 per cent minority interest in the companies for $15,000.

If the company receives the full allotment of the shares for sale it will own approximately 25.3 per cent in the Shaw companies.

Leveljump also updated shareholders on the progress of acquisitions announced September 28 and October 1.

In September, the company announced that it would acquire three Ontario diagnostic imaging clinics for $4.3 million. Financing has been secured, and the transaction is now expected to close at the end of January 2022.

Leveljump has been completing due diligence and audits of a U.S.-based telehealth business that the company announced it planned to acquire in October. Licensing and transition planning for the acquisition is now underway.

Finally, Leveljump announced that it has issued 300,000 options to each of its three new independent directors. The company also issued 500,000 options each to its two executive directors and 1.8 million options each to its CEO and CFO, which will be granted over the next three years.

Both the CEO and CFO have also agreed to convert $240,000 in accrued salary into common shares at $0.12 per share for a total of 2 million shares.

Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology. The company provides radiology solutions for hospitals, emergency rooms, and private clinics.

Shares in Leveljump Healthcare Corp. (JUMP) are up 4.35 per cent, trading at $0.12 per share as of 10:49 am EST.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.